{"organizations": [], "uuid": "c6395c14c2fd0733303bcc2d0504363a78ec87b3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-immutep-ltd-enters-into-clinical-t/brief-immutep-ltd-enters-into-clinical-trial-collaboration-with-merck-co-idUSFWN1QT03F", "country": "US", "domain_rank": 408, "title": "BRIEF-Immutep Ltd Enters Into Clinical Trial Collaboration With Merck & Co", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T03:14:00.000+02:00", "replies_count": 0, "uuid": "c6395c14c2fd0733303bcc2d0504363a78ec87b3"}, "author": "", "url": "https://www.reuters.com/article/brief-immutep-ltd-enters-into-clinical-t/brief-immutep-ltd-enters-into-clinical-trial-collaboration-with-merck-co-idUSFWN1QT03F", "ord_in_thread": 0, "title": "BRIEF-Immutep Ltd Enters Into Clinical Trial Collaboration With Merck & Co", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-immutep ltd", "sentiment": "negative"}, {"name": "brief-immutep ltd enters into clinical trial collaboration with merck & co", "sentiment": "negative"}, {"name": "immutep ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "merck & co reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12 (Reuters) - Immutep Ltd:\n* ENTERED INTO A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK & CO., INC\n* DEAL TO EVALUATE COMBINATION OF IMMUTEP’S IMMUNOTHERAPY PRODUCT CANDIDATE WITH MSD’S ANTI-PD-1 THERAPY KEYTRUDA IN A NEW CLINICAL TRIAL Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-03-12T03:14:00.000+02:00", "crawled": "2018-03-12T03:33:21.012+02:00", "highlightTitle": ""}